Showing results (3331-3340 of 6,517) with videos related to
Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|July 27, 2011
Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activityXiaoli Yan, Xiaojun Zhang, Yanzhong Wang, et al.Cancer Immunology, Immunotherapy : CII|June 2, 2011
A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responsesFrank Neumann, Boris Kubuschok, Kubilay Ertan, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
Tumorigenicity and H-2 expression of papillomavirus-transformed mouse cell linesA Laatikainen, H Karjalainen, H Jägerroos, et al.Cancer Immunology, Immunotherapy : CII|June 1, 2011
Targeting the extrinsic apoptosis signaling pathway for cancer therapyThomas J SayersCancer Immunology, Immunotherapy : CII|June 4, 2011
Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinomaLaura Alaniz, Manglio Rizzo, Mariana G Garcia, et al.Cancer Immunology, Immunotherapy : CII|June 11, 2011
Th17 and Th17-stimulated CD8⁺ T cells play a distinct role in Th17-induced preventive and therapeutic antitumor immunityManjunatha Ankathatti Munegowda, Yulin Deng, Sean J Mulligan, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1990
The immunological status of breast cancer patients during treatment with a new antiestrogen, toremifeneR Valavaara, J Tuominen, A ToivanenCancer Immunology, Immunotherapy : CII|May 7, 2011
Foxp3 expression in melanoma cells as a possible mechanism of resistance to immune destructionJunzhou Niu, Changli Jiang, Chunying Li, et al.Cancer Immunology, Immunotherapy : CII|April 12, 2011
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu miceRonald P Gladue, Timothy Paradis, Susan H Cole, et al.Cancer Immunology, Immunotherapy : CII|May 10, 2011
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Arcadi Cipponi, Grégoire Wieers, Nicolas van Baren, et al.Pageof 652